acenocoumarol and Endotoxemia

acenocoumarol has been researched along with Endotoxemia* in 1 studies

Trials

1 trial(s) available for acenocoumarol and Endotoxemia

ArticleYear
Acenocoumarol decreases tissue factor-dependent coagulation during systemic inflammation in humans.
    Clinical pharmacology and therapeutics, 2002, Volume: 71, Issue:5

    Coumarin derivatives are still widely used for prophylaxis of thromboembolic events and therefore represent important comparator substances for new anticoagulants. Measurement of the efficacy of such novel compounds in a human coagulation model with adequate biomarkers could be useful for early-phase clinical drug development. To evaluate the applicability of a well-established model of tissue factor-dependent coagulation for defining anticoagulant potency, we investigated the effects of acenocoumarol in experimental human endotoxemia.. In a randomized, controlled, 2-by-2 factorial design, healthy volunteers received an infusion of 2 ng/kg endotoxin or placebo after 18 days of pretreatment with acenocoumarol or placebo. Prothrombin fragment 1+2 (F(1+2)), soluble fibrin, and D-dimer were used as markers of thrombin and fibrin formation.. As expected, pretreatment with acenocoumarol decreased vitamin K-dependent coagulation factors, but it also decreased spontaneous thrombin formation. Acenocoumarol inhibited endotoxin-induced thrombin generation as measured by F(1+2) levels: endotoxin infusion increased F(1+2) levels 8-fold-from 0.5 to 4.1 nmol/L-in the placebo group, whereas peak F(1+2) levels reached only 1.0 nmol/L in subjects after acenocoumarol pretreatment. This inhibition was also reflected in decreased formation of soluble fibrin and decreased D-dimer levels, showing that depletion of endogenous coagulation factors limits the propagation of nonovert disseminated intravascular coagulation.. Human endotoxemia is a suitable tool for measurement of the efficacy of oral anticoagulants and therefore may become a valuable addition for expeditious pharmacodynamic characterization of lead compounds with anticoagulant potency.

    Topics: Acenocoumarol; Adult; Analysis of Variance; Anticoagulants; Biomarkers; Blood Coagulation Tests; Confidence Intervals; Dimerization; Double-Blind Method; Endotoxemia; Factor VIIa; Fibrin Fibrinogen Degradation Products; Humans; Inflammation; Infusions, Intravenous; Lipopolysaccharides; Male; Peptide Fragments; Pilot Projects; Platelet Count; Prothrombin; Solubility; Statistics, Nonparametric; Thromboplastin

2002